Voriconazole-Induced QT Interval Prolongation: A Prospective Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04502355

Enrollment

Registered

2020-08-06

Start date

2016-10-31

Completion date

2020-12-31

Last updated

2020-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Voriconazole Induced QT Interval Prolongation

Keywords

voriconazole, ECG, arrhythmia

Brief summary

The antifungal voriconazole is effective for the treatment of invasive fungal infections in immunocompromised patients. A serious adverse reaction is QT interval prolongation, which may precede life-threatening arrhythmias, such as torsades de pointes. Although ventricular arrhythmias are mentioned as a possible adverse effect of voriconazole, thus far, the incidence and clear recommendations for QT follow-up have not been published. This prospective observational study aimed at describing the incidence of voriconazole induced- QT interval prolongation in the pediatric population and determine the risk factors for this phenomenon.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 20 Years

Inclusion criteria

* oral or IV treatment with voriconazole

Exclusion criteria

* No data prior to initiation of voriconazole treatment on QT interval (baseline ECG) * Renal insufficiency or dialysis treatment

Design outcomes

Primary

Measure	Time frame
QT interval prolongation	up to three months of treatment

Countries

Israel

Outcome results